Drug Database
Back to search

Poland· PL-100487462

Byesilor

A liraglutide product containing liraglutidum, registered in Poland by Ranbaxy (Poland) Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC A10BJ02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedByesilorATCA10BJ02REGISTER NO.PL-100487462PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about liraglutidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Liraglutide is registered in 16 of 19 countries.

Countries holding a registration under ATC A10BJ02 (liraglutide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search liraglutide products by name

Liraglutide · ATC A10BJ02

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Liraglutidum
Manufacturer
Ranbaxy (Poland) Sp. z o.o.
Country
Poland (PL)
ATC code
A10BJ02
ATC class
Liraglutide
Defined daily dose
1.5 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991581565
  • gtin
    05909991581572

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

309 interactions on record for liraglutide.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check liraglutide against other medicinesHow interaction checks work

Liraglutide · interactions on record

309 records

  • 3 severe
  • 260 moderate
  • 46 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Liraglutide in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All liraglutide products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Ejulir, Lirabelin
  • Belgium · Byesilor, Zinnentis
  • Bulgaria · Зеглуксен
  • Czechia · Ejulir, Plyzari
  • Germany · Byesilor, Diavic
  • Denmark · Ejulir, Liraglutid "biogaran"
  • Estonia · Liraglutide Zentiva, Siluxir
  • Spain · Byesilor, Diavic
  • Finland · Diavic, Metlyra
  • France · Liendax, Liraglutide Biogaran
  • United Kingdom (Northern Ireland) · Diavic, Ligobesy
  • Croatia · Zegluxen
  • Hungary · Liendax
  • Ireland · Ejulir
  • Iceland · Ablymico, Liraglutide Stada
  • Italy · Byesilor, Diavic
  • Liechtenstein · Ablymico, Liraglutide Stada
  • Lithuania · Liraglutide Zentiva
  • Luxembourg · Zinnentis
  • Latvia · Liraglutide Zentiva, Siluxir
  • Netherlands · Byesilor, Diavic
  • Norway · Ablymico, Liraglutid Zentiva
  • Portugal · Liraglutido Farmoz, Liraglutido Pentafarma
  • Romania · Byesilor, Diavic
  • Sweden · Diavic, Ejulir
  • Slovakia · Sudaclin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e0051743-7612-438b-bd68-a01bb0a925e9
GET /v1/drugs/e0051743-7612-438b-bd68-a01bb0a925e9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
  "source": "urpl",
  "strength": "6 mg/ml",
  "packaging": "05909991581565 ¦ Rp ¦ 163045\n2 wstrzykiwacze 3 ml\n05909991581572 ¦ Rp ¦ 163046\n3 wstrzykiwacze 3 ml",
  "substance": "Liraglutidum 6 mg/ml",
  "common_name": "Liraglutidum",
  "pl_product_id": "100487462",
  "pozwolenie_nr": "29200",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-07-24"
}
API referenceMCP serverPlans

See everything about liraglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console